NEOG logo

Neogen Corporation Stock Price

NasdaqGS:NEOG Community·US$2.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

NEOG Share Price Performance

US$11.95
6.31 (111.88%)
US$13.00
Fair Value
US$11.95
6.31 (111.88%)
8.1% undervalued intrinsic discount
US$13.00
Fair Value
Price US$11.95
AnalystConsensusTarget US$13.00
AnalystHighTarget US$13.00
AnalystLowTarget US$12.00

NEOG Community Narratives

·
Fair Value US$13 8.1% undervalued intrinsic discount

NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
·
Fair Value US$13 8.1% undervalued intrinsic discount

Digital Transformation And Protein Demand Will Unlock Testing Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$12 0.4% undervalued intrinsic discount

Declining Demand And Integration Woes Will Dampen Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$13
8.1% undervalued intrinsic discount
Profit Margin
11.46%
Future PE
34.73x
Price in 2029
US$16.28
US$13
8.1% undervalued intrinsic discount
Profit Margin
11.88%
Future PE
37.54x
Price in 2029
US$16.46

Trending Discussion

No trending discussion available.

Updated Narratives

NEOG logo

NEOG: Transformation Plan And Higher R&D Spending Will Shape Balanced Outlook

Fair Value: US$12 0.4% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NEOG logo

NEOG: 2027 Guidance And Margin Outlook Will Frame Balanced Return Potential

Fair Value: US$13 8.1% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NEOG logo

NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook

Fair Value: US$13 8.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet and overvalued.

1 Risk
0 Rewards

Neogen Corporation Key Details

US$870.4m

Revenue

US$461.9m

Cost of Revenue

US$408.5m

Gross Profit

US$416.4m

Other Expenses

-US$7.9m

Earnings

Last Reported Earnings
May 31, 2026
Next Reporting Earnings
n/a
-0.036
46.93%
-0.91%
38.0%
View Full Analysis

About NEOG

Founded
1981
Employees
2636
CEO
Mikhael Nassif
WebsiteView website
www.neogen.com

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Recent NEOG News & Updates

Narrative Update Aug 15

NEOG: Transformation Plan And Higher R&D Spending Will Shape Balanced Outlook

Analysts have raised their price target for Neogen to $12.00 from $11, citing modest adjustments to fair value estimates, a slightly lower discount rate, a smaller expected revenue decline, a stable profit margin outlook, and a marginally higher assumed future P/E multiple. What’s in the News for Neogen Neogen reported fiscal Q4 2026 revenue of US$225.3 million and a net loss of US$11.3 million, with core revenue growth of 4.3%, mainly from the Food Safety segment.

Recent updates

No updates